CROSSJECT (ALCJ.PA)

Executive Summary

Crossject is a French specialty pharmaceutical company leveraging its proprietary ZENEO® needle-free auto-injector platform to develop rapid-acting emergency medications for life-threatening conditions, including epileptic seizures, acute adrenal crisis, and anaphylaxis. Founded in 1996 and headquartered in Dijon, the company is publicly traded on Euronext Growth (ALCJ.PA) with a market capitalization of approximately €104 million. Crossject’s platform addresses the limitations of traditional needle-based auto-injectors, offering more reliable drug delivery with reduced needlestick risk and enhanced patient compliance. The company is focused on advancing its pipeline of ZENEO-based products, which are designed to deliver critical medications in seconds during emergencies.

Upcoming Catalysts (preview)

• Q3 2026Regulatory submission for ZENEO® Epinephrine in the EU70% success
• Q4 2026Top-line data from Phase III trial of ZENEO® Midazolam for seizure clusters60% success
• H1 2026Strategic partnership or licensing deal for ZENEO® platform in a new indication50% success